Edition:
United States

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

27.68USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$27.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
153,747
52-wk High
$34.98
52-wk Low
$13.06

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $1,068.76
Shares Outstanding(Mil.): 38.61
Dividend: --
Yield (%): --

Financials

  CTMX.OQ Industry Sector
P/E (TTM): -- 199.23 33.71
EPS (TTM): -1.84 -- --
ROI: -27.53 -0.66 13.09
ROE: -92.74 -2.84 14.92

BRIEF-Cytomx Therapeutics Provides Operational Update

* CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

Mar 07 2018

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

Dec 18 2017

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

Nov 28 2017

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

Nov 07 2017

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

Oct 24 2017

Competitors

Earnings vs. Estimates